Who We Are
Data
MTCC includes a dedicated Data Coordinating Center with extensive experience managing complex, multisite datasets. Our capabilities include development of 21 CFR Part 11–compliant databases, case report form design, data verification and query resolution.
Learn More About Our Data Management
Expertise
We offer multidisciplinary expertise in study design, biostatistics and clinical operations. Our team applies innovative, rigorous approaches across the research lifecycle to ensure all outcomes are reproducible and impactful.
Learn More About Our Expertise
Coordinating
MTCC’s Coordinating Center manages complex multisite studies through protocol development, site training and milestone tracking. Our leadership ensures consistent operations and cross-site collaboration to deliver high-impact research on schedule.
Learn More About Our Coordinating Expertise
Regulatory
Our regulatory specialists navigate complex compliance requirements, handling IRB coordination, protocol reviews and safety reporting. We streamline approvals and manage risks to ensure all research is ethical, timely and compliant.
Learn More About Our Regulatory Services
Mission
To provide end to end study support to conduct multisite trials in a manner that is scientifically rigorous, operationally efficient and compliant.
Who We Are
The Ohio State University Multisite Trials Coordinating Center (MTCC) brings together nationally recognized expertise across the full lifecycle of multisite clinical research. Our multidisciplinary leadership and integrated teams provide end‑to‑end coordination for complex studies, ensuring scientific rigor, operational efficiency, regulatory compliance and high‑quality data.
MTCC experts have decades of experience designing and leading multisite clinical trials, including randomized controlled trials, pragmatic trials, observational studies and implementation studies, across academic, federally funded and industry‑sponsored settings. Our collective experience spans therapeutic areas such as cardiovascular disease, cancer, pancreatic disease, genomic medicine, pediatrics, mental health and rare diseases, as well as trials involving vulnerable populations and multinational sites.
